Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 4, 2016, Pages 608-617

  Rahtu Korpela, Lea ^a   Määttä, Jenni ^a   Dimova, Elitsa Y ^a   Hörkkö, Sohvi ^a,b   Gylling, Helena ^c   Walkinshaw, Gail ^d   Hakkola, Jukka ^a   Kivirikko, Kari I ^a   Myllyharju, Johanna ^a   Serpi, Raisa ^a   Koivunen, Peppi ^a  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d FIBROGEN INC   (United States)

Author keywords

atherosclerosis; cholesterol; hypoxia; immunology; inflammation

Indexed keywords

AUTOANTIBODY; CHOLESTEROL; FG 4497; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR; UNCLASSIFIED DRUG; AUTACOID; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; EGLN1 PROTEIN, MOUSE; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; ENZYME INHIBITOR; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL AGGREGATION; CELL COUNT; CELL SIZE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME INHIBITION; GENE; GENE EXPRESSION; GLUCOSE METABOLISM; HEART PROTECTION; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; LIVER; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; WEIGHT GAIN; WHITE ADIPOSE TISSUE; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; AORTIC DISEASES; BLOOD; C57BL MOUSE; CELL CULTURE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; METABOLISM; OBESITY; PATHOLOGY; TIME FACTOR;

ADIPOSE TISSUE, WHITE; ADIPOSITY; ANIMALS; AORTA; AORTIC DISEASES; ATHEROSCLEROSIS; AUTOANTIBODIES; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELLS, CULTURED; CHOLESTEROL; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LIPOPROTEINS, LDL; LIVER; MACROPHAGES; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; PROTEIN STABILITY; RECEPTORS, LDL; TIME FACTORS; WEIGHT GAIN;

EID: 84957582000     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.307136     Document Type: Article

References (31)

1. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30:393-402. doi: 10.1016/j.molcel.2008.04.009.
2. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148:399-408. doi: 10.1016/j.cell.2012.01.021.
3. Myllyharju J, Koivunen P. Hypoxia-inducible factor prolyl 4-hydroxylases: common and specific roles. Biol Chem. 2013;394:435-448. doi: 10.1515/hsz-2012-0328.
4. Laitala A, Aro E, Walkinshaw G, Mäki JM, Rossi M, Heikkilä M, Savolainen ER, Arend M, Kivirikko KI, Koivunen P, Myllyharju J. Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis. Blood. 2012;120:3336-3344. doi: 10.1182/blood-2012-07-441824.
5. Takeda K, Ho VC, Takeda H, Duan LJ, Nagy A, Fong GH. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol. 2006;26:8336-8346. doi: 10.1128/MCB.00425-06.
6. Ben-Shoshan J, Afek A, Maysel-Auslender S, Barzelay A, Rubinstein A, Keren G, George J. HIF-1alpha overexpression and experimental murine atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:665-670. doi: 10.1161/ATVBAHA.108.183319.
7. Gao L, Chen Q, Zhou X, Fan L. The role of hypoxia-inducible factor 1 in atherosclerosis. J Clin Pathol. 2012;65:872-876. doi: 10.1136/ jclinpath-2012-200828.
8. Hyvärinen J, Hassinen IE, Sormunen R, Mäki JM, Kivirikko KI, Koivunen P, Myllyharju J. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase- 2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem. 2010;285:13646-13657. doi: 10.1074/jbc. M109.084855.
9. Rahtu-Korpela L, Karsikas S, Hörkkö S, Blanco Sequeiros R, Lammentausta E, Mäkelä KA, Herzig KH, Walkinshaw G, Kivirikko KI, Myllyharju J, Serpi R, Koivunen P. HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction. Diabetes. 2014;63:3324-3333. doi: 10.2337/ db14-0472.
10. Taniguchi CM, Finger EC, Krieg AJ, Wu C, Diep AN, LaGory EL, Wei K, McGinnis LM, Yuan J, Kuo CJ, Giaccia AJ. Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes. Nat Med. 2013;19:1325-1330. doi: 10.1038/nm.3294.
11. Wei K, Piecewicz SM, McGinnis LM, et al. A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. Nat Med. 2013;19:1331-1337. doi: 10.1038/nm.3295.
12. Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda). 2009;24:97-106. doi: 10.1152/ physiol.00045.2008.
13. Spann NJ, Garmire LX, McDonald JG, et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell. 2012;151:138-152. doi: 10.1016/j.cell.2012.06.054.
14. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde- modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A. 1995;92:821-825.
15. Kyaw T, Tay C, Krishnamurthi S, Kanellakis P, Agrotis A, Tipping P, Bobik A, Toh BH. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res. 2011;109:830-840. doi: 10.1161/ CIRCRESAHA.111.248542.
16. Binder CJ. Natural IgM antibodies against oxidation-specific epitopes. J Clin Immunol. 2010;30(suppl 1):S56-S60. doi: 10.1007/ s10875-010-9396-3.
17. Tsiantoulas D, Gruber S, Binder CJ. B-1 cell immunoglobulin directed against oxidation-specific epitopes. Front Immunol. 2012;3:415. doi: 10.3389/fimmu.2012.00415.
18. Svenson KL, Ahituv N, Durgin RS, Savage H, Magnani PA, Foreman O, Paigen B, Peters LL. A new mouse mutant for the LDL receptor identified using ENU mutagenesis. J Lipid Res. 2008;49:2452-2462. doi: 10.1194/ jlr.M800303-JLR200.
19. Kasivisvanathan V, Shalhoub J, Lim CS, Shepherd AC, Thapar A, Davies AH. Hypoxia-inducible factor-1 in arterial disease: a putative therapeutic target. Curr Vasc Pharmacol. 2011;9:333-349.
20. Ezzati M, Horwitz ME, Thomas DS, Friedman AB, Roach R, Clark T, Murray CJ, Honigman B. Altitude, life expectancy and mortality from ischaemic heart disease, stroke, COPD and cancers: national population- based analysis of US counties. J Epidemiol Community Health. 2012;66:e17. doi: 10.1136/jech.2010.112938.
21. Matsuura H, Ichiki T, Inoue E, Nomura M, Miyazaki R, Hashimoto T, Ikeda J, Takayanagi R, Fong GH, Sunagawa K. Prolyl hydroxylase domain protein 2 plays a critical role in diet-induced obesity and glucose intolerance. Circulation. 2013;127:2078-2087. doi: 10.1161/ CIRCULATIONAHA.113.001742.
22. Michailidou Z, Morton NM, Moreno Navarrete JM, West CC, Stewart KJ, Fernández-Real JM, Schofield CJ, Seckl JR, Ratcliffe PJ. Adipocyte pseudohypoxia suppresses lipolysis and facilitates benign adipose tissue expansion. Diabetes. 2015;64:733-745. doi: 10.2337/ db14-0233.
23. Ide T, Shimano H, Yahagi N, Matsuzaka T, Nakakuki M, Yamamoto T, Nakagawa Y, Takahashi A, Suzuki H, Sone H, Toyoshima H, Fukamizu A, Yamada N. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol. 2004;6:351-357. doi: 10.1038/ncb1111.
24. Leavens KF, Birnbaum MJ. Insulin signaling to hepatic lipid metabolism in health and disease. Crit Rev Biochem Mol Biol. 2011;46:200-215. doi: 10.3109/10409238.2011.562481.
25. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125-1131. doi: 10.1172/JCI15593.
26. Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in atherosclerosis. Circ Res. 2014;114:1743-1756. doi: 10.1161/CIRCRESAHA.113.301145.
27. Eltzschig HK, Bratton DL, Colgan SP. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat Rev Drug Discov. 2014;13:852-869. doi: 10.1038/nrd4422.
28. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol. 2008;586(pt 17):4055-4059. doi: 10.1113/jphysiol.2008.157669.
29. Clambey ET, McNamee EN, Westrich JA, Glover LE, Campbell EL, Jedlicka P, de Zoeten EF, Cambier JC, Stenmark KR, Colgan SP, Eltzschig HK. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci U S A. 2012;109:E2784- E2793. doi: 10.1073/pnas.1202366109.
30. Meng X, Yang J, Dong M, Zhang K, Tu E, Gao Q, Chen W, Zhang C, Zhang Y. Regulatory T cells in cardiovascular diseases. Nat Rev Cardiol. 2015. doi: 10.1038/nrcardio.2015.169.
31. Eckle T, Brodsky K, Bonney M, Packard T, Han J, Borchers CH, Mariani TJ, Kominsky DJ, Mittelbronn M, Eltzschig HK. HIF1A reduces acute lung injury by optimizing carbohydrate metabolism in the alveolar epithelium. PLoS Biol. 2013;11:e1001665. doi: 10.1371/journal. pbio.1001665.